Intelligent Bio Solutions Inc. (NASDAQ: INBS) is making strides in the medical technology sector with its groundbreaking fingerprint-based drug screening system. CEO Harry Simeonidis recently appeared on The BioMedWire Podcast to discuss the technology's capabilities and the company's strategic plans for global expansion. The system, which analyzes sweat from fingerprints to detect drug use, offers a faster and more cost-effective alternative to traditional drug testing methods. Currently operational in approximately 20 countries, Intelligent Bio Solutions is awaiting FDA approval to enter the U.S. market by the second half of 2025.
The implications of this technology are significant for industries where drug testing is critical for safety, such as construction, manufacturing, and transportation. By providing results in under ten minutes, the system could drastically reduce downtime and costs associated with drug screening, while also offering a less invasive option for employees. With its potential for broader applications beyond workplace testing, Intelligent Bio Solutions' technology represents a notable advancement in the field of medical diagnostics.
